NCT06898554 Spinal and Supraspinal Control in Chronic Ankle Instability
| NCT ID | NCT06898554 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ayca Yagcioglu |
| Condition | Ankle Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-11-15 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ankle sprains are common sports injuries that often lead to chronic ankle instability (CAI). Patients with CAI experience deficits in neuromuscular control (NMC), including proprioception and strength. It is believed that damage to the ankle's ligament mechanoreceptors and the peroneal nerve after the initial ankle sprain can cause alterations in NMC, resulting in postural control and dynamic joint stability dysfunction. Inflammation related to recurrent ankle sprains may also contribute to neuromuscular impairments. Evidence suggests that bilateral postural control deficits occur after an ankle sprain, suggesting alterations in the central nervous system (CNS). Rehabilitation for CAI has been shown to lead to bilateral improvements in NMC, potentially due to neural alterations at both the spinal and supraspinal levels. Cross-education, which refers to the muscular crossed effect of unilateral training, has also been proposed as a mechanism for improving contralateral strength in neurologically healthy individuals. While the exact mechanisms underlying cross-education are not yet fully understood, evidence suggests that it involves neural adaptations at both spinal and supraspinal levels. This study aims to investigate the cross-education effect of a 6-week, unilateral balance training on corticomotor excitability, motor neuron pool excitability, and static and dynamic balance in athletes with chronic ankle instability.
Eligibility Criteria
Inclusion Criteria: * Volunteering to participate in the study, * Being an athlete between the ages of 18-25, * Being a player in a field team sport such as basketball, volleyball, and handball, * Having a history of at least 2 significant grade II LAS diagnosed by a physician, * Related inflammatory symptoms, "giving away" sensation, obtaining a score ≤25 from the Cumberland Ankle Instability Tool (CAIT), * A score \<90% for the activities of daily living subscale and \<80% for the sport subscale from the Foot and Ankle Ability Measure, * Recurrent episodes of LAS of the injured ankle which occurred within at least 12 months. Exclusion Criteria: * Acute injury of lower extremity musculoskeletal structures in the last three months, * Orthopedic surgery in any of the lower extremities, * Bilateral ankle instability, * Vestibular or balance disorder
Contact & Investigator
Berrin Aktekin, MD, Professor
PRINCIPAL INVESTIGATOR
Yeditepe University Hospital
Frequently Asked Questions
Who can join the NCT06898554 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Ankle Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898554 currently recruiting?
Yes, NCT06898554 is actively recruiting participants. Contact the research team at ayca.yagcioglu@yeditepe.edu.tr for enrollment information.
Where is the NCT06898554 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06898554 clinical trial?
NCT06898554 is sponsored by Ayca Yagcioglu. The principal investigator is Berrin Aktekin, MD, Professor at Yeditepe University Hospital. The trial plans to enroll 30 participants.